CUTISS has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M.

CUTISS and Tecan partner to advance the automation of bioengineered human skin tissue manufacturing.

CUTISS AG has announced a long-term Phase 2 trial data update for denovoSkin™, the bio-engineered skin graft that could redefine reconstructive and burn surgery.

Celebration at the end of this year for CUTISS AG as the team receives authorization from EMA for the Phase 3 clinical trial for CUTISS’ lead product, denovoSkin™.

In a compassionate reconstructive procedure, denovoSkin™ was grafted on a pediatric patient, marking the first use of denovoSkin™ in the U.S. and the first use of denovoSkin™ in such a surgery.

Venturelab recently spoke to our former Project Leader of denovoSkin who is now Co-Founder and CEO of CUTISS AG. Learn more about her experience with a biotech startup and what she would do differently.

Our alumni project, denovoSkin (aka CUTISS), has announced positive interim analysis on efficacy from the Phase 2 clinical trial of its lead product denovoSkin™ in patients undergoing reconstructive skin surgery due to various conditions. (Image credit: CUTISS AG)

Our alumni project, denovoSkin (now known as CUTISS AG) has successfully closed its first CHF 25 million in its Series C funding round. This first closing allows CUTISS to enter Phase 3 clinical trials for its personalized skin therapy denovoSkin, which recently announced positive results in Phase 2.

Cutiss has published the results of a one-year study on its skin alternative denovoSkin. The data from the Phase 2 clinical trial in adult and adolescent severe burn patients are positive. (Image credit: Swisstrade / CUTISS AG)